



What's Hot

ACW - Actinogen Medical Limited today closed up 10% to finish at 5.5c on \$420k stock traded. The reason they are up today is because they have provided an update on the recruitment progress for its landmark Alzheimer's disease trial, XanADu. XanADu is assessing the efficacy and safety of Xanamem in the treatment of Alzheimer's disease.

I am catching up with Dr Ketelbey later this week as I am very interested in the stock and the space they are in, so hopefully I can give you a more detailed update after I catch up with him.

Some highlights on today;'s news are listed below:

Strong Recruitment Progress in Alzheimer's Trial

- Enrolment into XanADu remains robust and on track
- Total of 72 patients enrolled, representing 41% of the full enrolment
- Study on track to enrol the final patient in Q4 this year
- Xanamem has the potential to provide a global solution to a significant unmet medical need

- Actinogen's novel approach to treating Alzheimer's disease represents a compelling investment opportunity

Actinogen Medical (ASX: ACW) is pleased to provide an update on the recruitment progress for its landmark Alzheimer's disease trial, XanADu. XanADu is assessing the efficacy and safety of Xanamem in the treatment of Alzheimer's disease.

As of 12th February, 72 patients have been enrolled into the trial, representing 41% of the total enrolment of 174 patients. Additionally, more than 30 patients have completed the study, including the 12-week treatment period and the 4-week follow-up.

The study continues on schedule, with the final patient expected to be enrolled by Q4 this year.

Alzheimer's disease is already the leading cause of death in Australian women, and second only to cardiovascular disease in Australian men (ABS 2017). The future cost of managing Alzheimer's disease is likely to overwhelm available health budgets, and with only four marginally effective drugs available to treat the condition, there is an urgent need to develop new therapies to manage the disease.

Should Xanamem be shown to be effective in the treatment of Alzheimer's disease, it would be the most meaningful advance in Alzheimer's treatment in decades, representing a rare and compelling investment opportunity.

"Having spent the majority of my career working within the biotech venture capital investment industry, I am well aware of the enormous challenges and commonplace delays involved in clinical trial enrolment. It is encouraging therefore to see the excellent progress being made by the Actinogen Medical team in enrolling patients into the XanADu trial. It's an impressive achievement

to be right on schedule with patient enrolment.” said Dr Geoff Brooke, Chairman Actinogen Medical

[Subscribe Here](#)

Go Hard

Nick Kelso

Client Adviser

p: 02 8379 2962

m: 0404 003 613

e: nk@huntercap.com.au

For Hunter Capital Advisors Pty Ltd Disclaimer click [here](#)

For a free subscription to the full report please email Nick Kelso



The idea of this report is to be informative and hopefully point out stocks that you wouldn't ordinarily have seen during the day.

This report IS NOT personal advice.

It is very important to refer to the ASX website for information on any stocks that are contained in this report and as always please consult your financial adviser before acting .

This report is written by myself and the views in this report may not accurately reflect the same views as Hunter Capital.

If I have bought stocks or hold them I will let you know about it but it doesn't mean that it is a good

buy.

If looking at anything mentioned in this report **please consult your financial adviser before acting.**

This report is written by myself, I don't have the luxury of having a big team to help with this report there will be errors in this report, spelling mistakes, grammar mistakes, closing prices etc etc.

Please check all the facts yourself and don't take what I have written quickly between 4pm & 6pm as gospel.

If you are a broker or even investor that is receiving this report more than happy to get ideas and feedback on stocks that you think I should be looking at or writing about.

I will not tolerate any keyboard warriors.

' The trend is your friend until the bend at the end'

If you don't like what I write or my writing style please just email me unsubscribe and you will be taken off the list.

I also have a stockbroking business to run during the day so anyone that does send me queries or ideas I will try and get back to you as soon as possible.

If you would like to be offered stock in the wide variety of placements and IPOs that I am showed please let me know and I will add you to my list so you have a chance to bid for the stock when it becomes available.

708 or sophisticated investors happy to show placements.

Non 708 investors happy to show any deals that are available for you to participate in.

My company and I may receive fees from some companies mentioned in this report.

If you are receiving this from someone else please just send me an email directly and would be happy to add you to my distribution list.

And to finish off one of the world's longest disclaimers

Go Hard